Circulating Protein Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas

Anticancer Res. 2019 Aug;39(8):3981-3989. doi: 10.21873/anticanres.13553.

Abstract

Uterine sarcomas are rare but very aggressive. Uterine myomas, on the other hand, are the most common benign tumors of the uterus. Currently there is no diagnostic technique available to distinguish them with certainty. This study aimed to summarize the published literature concerning protein-based biomarkers in the peripheral blood that can assist in this difficult differential diagnosis. In total, 48 articles, published between 1990 and 2017, were included. Most studies (n=37) concerned soft tissue sarcomas, while 11 discussed uterine sarcomas specifically. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), interleukins (IL), cancer antigen 125 (CA 125), lactate dehydrogenase, gangliosides (LDH) and growth differentiation factor 15 (GDF-15) are the most studied proteins in soft tissue sarcomas, including uterine sarcomas. Future research on improving sarcoma diagnosis should include these proteins.

Keywords: Uterine sarcoma; biomarker; diagnosis; immunosuppression; review; serum.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / blood
  • Cell Differentiation / genetics
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Leiomyoma / blood*
  • Leiomyoma / pathology
  • Muscle Neoplasms / blood
  • Muscle Neoplasms / pathology
  • Neoplasms / blood*
  • Neoplasms / pathology
  • Sarcoma / blood*
  • Sarcoma / pathology
  • Uterine Neoplasms / blood*
  • Uterine Neoplasms / pathology

Substances

  • Biomarkers, Tumor